

Professional Medical Society Consensus Guidelines: Patient Selection Criteria for Accelerated Partial Breast Irradiation					
	ABS ¹	ASBS ²	ACRO ³	ASTRO ⁴	
				Suitable	Cautionary
Age	≥45	≥45	≥45	≥50	40-49 years if all other criteria for “suitable” are met 50 y if patient has at least 1 of the pathologic factors below and does not have any “unsuitable” factors Pathologic factors: <ul style="list-style-type: none"> • Size 2.1-3.0 cm a • T2 • Close margins (b2 mm) • Limited/focal LVSI • ER(-) • Clinically unifocal with total size 2.1-3.0 cm b • Invasive lobular histology • Pure DCIS ≤3 cm if criteria for “suitable” not fully met • EIC ≤3 cm
Diagnosis	All invasive histologies and ductal carcinoma in situ (DCIS)	Invasive ductal carcinoma or ductal carcinoma in situ (DCIS)	Invasive ductal carcinoma or DCIS	Invasive ductal or other favorable subtypes (ie: mucinous, tubular, colloid) Pure DCIS if: <ul style="list-style-type: none"> • Screen-detected • Low to intermediate nuclear grade • Size ≤ 2.5 cm • Resected with margins negative at ≥ 3 mm 	Pure DCIS if ≤ 3 cm and does not meet criteria for “suitable”
Tumor Size	≤3cm	≤3cm	≤3cm	≤2cm	2.1-3.0cm
Surgical Margins	Negative microscopic surgical margins of excision	Negative microscopic surgical margins of excision	Negative microscopic surgical margins of excision	Negative by ≥2 mm	Close (<2mm)
Nodal Status	N0	N0	N0	N0 (i-,i+)	

References: **1.** C. Shah, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. October, 2017. [http://www.brachyjournal.com/article/S1538-4721\(17\)30462-2/fulltext](http://www.brachyjournal.com/article/S1538-4721(17)30462-2/fulltext). **2.** Consensus statement for accelerated partial breast irradiation. The American Society of Breast Surgeons. December 8, 2005. **3.** American College of Radiation Oncology Statement on Partial Breast Irradiation. September, 2008. **4.** Correa, C et al., Accelerated Partial Breast Irradiation: Update of an ASTRO Evidence-Based Consensus Statement. *Practical Radiation Oncology*, APBI CONSENSUS STATEMENT UPDATE 2017 (Published on-line September 17, 2016). [http://www.practicalradonc.org/article/S1879-8500\(16\)30184-9/fulltext](http://www.practicalradonc.org/article/S1879-8500(16)30184-9/fulltext) **MISC-03314 Rev 003.** © 2017 Hologic, Inc. Hologic, 5-Day Targeted Therapy and associated logos are trademarks or registered trademarks of Hologic and/or Hologic subsidiaries in the United States and/or other countries. All other trademarks, registered trademarks, and product names are the property of their respective owners. The information provided here is for educational purposes only. This information should in no way be considered or represented as offering medical advice.